Keysight Debuts 1.6T Platform and First-of-its-Kind Software to Automate Validation of Network Interconnect Performance

Keysight Debuts 1.6T Platform and First-of-its-Kind Software to Automate Validation of Network Interconnect Performance

  • Versatile 1.6 Terabit Ethernet platform in portable benchtop or rackmount solutions, with application support for validating silicon chips to network equipment performance
  • Validates functionality and reliability in 200GE to1600GE interconnects in high-speed Ethernet and AI network infrastructures
  • Delivers a new methodology that transforms how interconnects are validated, setting a new standard for efficiency, accuracy, and automation

SANTA ROSA, Calif.–(BUSINESS WIRE)–Keysight Technologies, Inc. (NYSE: KEYS) announced the Interconnect Test System (ITS), an advanced software solution, and the Interconnect and Network Performance Tester 1600GE (INPT-1600GE) hardware traffic emulator it runs on. This cohesive solution validates AI infrastructure, network components, and data center interconnects from 200GE to 1600GE, expanding on the capabilities of the recently announced Interconnect and Network Performance Tester 800GE benchtop. The ITS software runs on both the 800GE and 1600GE Interconnect and Network Performance Tester platforms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326500768/en/

The Interconnect and Network Performance Tester 1600GE is the industry’s most versatile 1.6T platform and is available as a portable benchtop or rackmount solution.

The Interconnect and Network Performance Tester 1600GE is the industry’s most versatile 1.6T platform and is available as a portable benchtop or rackmount solution.

For decades, validating network interconnect performance required a manual, time-consuming process with limited or no automation and needed advanced programming skills to write scripts. That process also lacked a centralized system to organize and store interconnect data and reports, making tracking and replicating tests and configurations difficult. With the increasing diversity and scale of AI and data center interconnects, these traditional test methods cannot accurately predict and measure the reliability of today’s complex production networks.

The new Interconnect and Network Performance Tester 1600GE, with ITS software, delivers a holistic system that can organize, store, and use data intelligently to automate interconnect validation in high-speed Ethernet networks and AI data centers. Benefits of the solution include:

  • Adaptable and versatile high-speed Ethernet platform The INPT-1600GE platform is lightweight and office quiet, supporting high power consumption optical receivers up to 40 watts. Available as a portable benchtop unit or rackmount chassis, both models support 1x1600GE, 2x800GE, 4x400GE, and 8x200GE to validate a broad range of Ethernet devices and interconnects that use 212Gb/s electrical lane interfaces. The benchtop model has a built-in handle for easy movement inside or outside the lab. The INPT-1600GE assesses the reliability, stability, and interoperability of silicon chips, optical transceivers, active cables, and networking equipment at speeds from 200GE to 1600GE PAM4 for layers 1 through 3 on any port.
  • Redefines interconnect data storage and organization – The ITS software includes a first-of-its-kind, US patent pending Interconnect Library (IL) that introduces a new way to organize, retrieve, and use interconnect data, including Common Management Interface Specification (CMIS) data. CMIS standardizes how high-speed interconnects are programmed and how the data is retrieved and used in networking systems. This cutting-edge library organizes all data and creates a comprehensive record that can be used to create and execute new tests. Once a record is created, it is automatically added to the IL self-serve database, where users can retrieve, reuse, edit, and update records. This dramatically increases productivity and accelerates the creation of automated test suites without advanced programming.
  • Optimize interconnect validation efficiency – The browser-based ITS software includes a robust and fast graphical user interface (GUI) that allows multiple users to simultaneously run or schedule tests using the application’s advanced multi-user test scheduler. Using this tool increases test case throughput, allowing more tests to run unattended by a greater number of users.
  • Automated report generator – Allows users to report on all the data from the IL records, including test results and CMIS data that includes PASS/FAIL information. This helps streamline the development process for interconnects and can also be used for manufacturing test applications using automated reports.

Khushrow Machhi, Senior Director of Marketing, Physical Layer Products Division at Broadcom, said: “As the industry moves toward 1.6T networking, ensuring signal integrity and error correction at these unprecedented speeds is critical. Broadcom is excited to collaborate with Keysight in developing cutting-edge testing solutions that address the challenges of higher modulation schemes, SerDes advancements, and forward error correction. Our combined expertise will help accelerate the deployment of 1.6T technology, paving the way for the future of high-speed data centers and AI-driven infrastructure.”

Andy Moorwood, Vice President, Hardware Engineering, Network Test & Security Solutions, Keysight, said: “Keysight’s ITS software is the industry’s first comprehensive solution for validating performance in high-speed Ethernet and AI data center interconnects. It helps reduce device failures and drastically reduces the time needed to characterize various interconnects. Moving from a manual and tedious process to one that enables faster, more accurate test suite automation without complex programming significantly boosts productivity.”

Ram Periakaruppan, Vice President and General Manager, Network Test & Security Solutions, Keysight, said: “Keysight is working with the majority of global standards bodies and manufacturers of silicon chips, optical and copper interconnects using 224Gb/s electrical lane interfaces to accelerate development of the ecosystem for 800GE and 1.6T AI network infrastructures. Our 1.6T and 800GE hardware platforms, combined with the ITS software, enable critical interconnect performance evaluations and tremendous gains in testbed productivity. This equips our customers with the tools they need to deploy highly stable and reliable solutions into their networks.”

Keysight will showcase the ITS software and high-speed Ethernet hardware platform in booth #1301 from April 1 – April 3 at the OFC Conference, Moscone Center, San Francisco, CA

Resources

About Keysight Technologies

At Keysight (NYSE: KEYS), we inspire and empower innovators to bring world-changing technologies to life. As an S&P 500 company, we’re delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. We’re a global innovation partner enabling customers in communications, industrial automation, aerospace and defense, automotive, semiconductor, and general electronics markets to accelerate innovation to connect and secure the world. Learn more at Keysight Newsroom and www.keysight.com.

Keysight Media Contacts


Andrea Mueller

[email protected]

Fusako Dohi

Asia

+81 42 660-2162

[email protected]

Jenny Gallacher

Europe

+44 (0) 7800 737 982

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Telecommunications Software Networks Internet Hardware Electronic Design Automation Data Management Consumer Electronics Artificial Intelligence

MEDIA:

Photo
Photo
The Interconnect and Network Performance Tester 1600GE is the industry’s most versatile 1.6T platform and is available as a portable benchtop or rackmount solution.
Logo
Logo

Old Dominion Freight Line to Webcast First Quarter 2025 Conference Call

Old Dominion Freight Line to Webcast First Quarter 2025 Conference Call

THOMASVILLE, N.C.–(BUSINESS WIRE)–
Old Dominion Freight Line, Inc. (Nasdaq: ODFL) announced today that it plans to release its first quarter 2025 financial results before opening of trading on Wednesday, April 23, 2025. The Company will also hold a conference call to discuss its financial results and outlook at 10:00 a.m. (Eastern Time) on Wednesday, April 23, 2025.

An online, real-time webcast of Old Dominion’s quarterly conference call will be available at ir.odfl.com on Wednesday, April 23, 2025, at 10:00 a.m. (Eastern Time). The online replay will be available at approximately 1:00 p.m. (Eastern Time) and continue for 30 days. A telephonic replay of the call can be accessed starting at 1:00 p.m. (Eastern Time) and will be available through April 30, 2025, at 1-877-344-7529, access code 3942957.

Old Dominion Freight Line, Inc. is one of the largest North American LTL motor carriers and provides regional, inter-regional and national LTL services through a single integrated, union-free organization. Our service offerings, which include expedited transportation, are provided through an expansive network of service centers located throughout the continental United States. The Company also maintains strategic alliances with other carriers to provide LTL services throughout North America. In addition to its core LTL services, the Company offers a range of value-added services including container drayage, truckload brokerage and supply chain consulting.

Adam N. Satterfield

Executive Vice President and

Chief Financial Officer

(336) 822-5721

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Supply Chain Management Trucking Rail Retail Logistics/Supply Chain Management Transport Other Transport

MEDIA:

Logo
Logo

The Gross Law Firm Notifies TELUS International (Cda) Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – TIXT

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of TELUS International (Cda) Inc. (NYSE: TIXT).

Shareholders who purchased shares of TIXT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/telus-international-loss-submission-form/?id=138503&from=3 

CLASS PERIOD: February 16, 2023 to August 1, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s AI Data Solutions offerings required the cannibalization of its higher-margin offerings; (2) Telus International’s declining profitability was tied to the Company’s drive to develop AI capabilities; (3) Telus International’s shift toward AI put greater pressure on the Company’s margins than previously disclosed; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE: March 31, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/telus-international-loss-submission-form/?id=138503&from=3 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of TIXT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 31, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018 
Email: [email protected] 
Phone: (646) 453-8903



Zynex, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – ZYXI

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).

Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=138526&from=3

CLASS PERIOD: March 13, 2023 to March 11, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; (3) the Company’s practice of filing false claims drew scrutiny from insurers, including the U.S. military health insurance program, Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE: May 19, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=138526&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ZYXI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 19, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903



GSK plc Class Action: The Gross Law Firm Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – GSK

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).

Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=138509&from=3

CLASS PERIOD: February 5, 2020 to August 14, 2022

ALLEGATIONS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators.” GSK also stated that it was “continuing with investigations into the potential source of NDMA.” Defendants also assured investors that “GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients,” findings that were “consistent with other ranitidine data published prior to 2019.” Finally, defendants claimed that they could not “quantify or reliably estimate the liability.” These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.

DEADLINE: April 7, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=138509&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of GSK during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903



Class Action Filed Against ICON Public Limited Company (ICLR) – April 11, 2025 Deadline to Join – Contact The Gross Law Firm

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR).

Shareholders who purchased shares of ICLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/icon-public-limited-company-loss-submission-form/?id=138494&from=3

CLASS PERIOD: July 27, 2023 to October 23, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a)ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company’s client base; (b)ICON’s purported functional service provision and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d)ICON’s customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e)ICON’s two largest customers were diversifying their clinical research organization providers away from the Company; (f)as a result of (a)-(e) above, ICON’s reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON’s services; and (g)as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the Class Period and such guidance lacked a reasonable factual basis.

DEADLINE: April 11, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/icon-public-limited-company-loss-submission-form/?id=138494&from=3 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ICLR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 11, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903



Investors who lost money on Walgreens Boots Alliance, Inc. (WBA) should contact The Gross Law Firm about pending Class Action – WBA

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA).

Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/walgreens-boots-alliance-inc-loss-submission-form-2/?id=138504&from=3 

CLASS PERIOD: April 2, 2020 to January 16, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) contrary to the Company’s purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement for the same; (ii) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny, civil liability, and reputational harm; (iii) Walgreens’ revenues from the sale of prescription medications were unsustainable to the extent that they derived from unlawful conduct; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

DEADLINE: March 31, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/walgreens-boots-alliance-inc-loss-submission-form-2/?id=138504&from=3 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of WBA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 31, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903



Shareholders that lost money on Sana Biotechnology, Inc. (SANA) should contact The Gross Law Firm about pending Class Action – SANA

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).

Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=138493&from=3

CLASS PERIOD: March 17, 2023 to November 4, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

DEADLINE: May 20, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=138493&from=3 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SANA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 20, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903



The Gross Law Firm Reminds Integral Ad Science Holding Corp. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 31, 2025 – IAS

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Integral Ad Science Holding Corp. (NASDAQ: IAS).

Shareholders who purchased shares of IAS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/integral-ad-science-loss-submission-form/?id=138490&from=3

CLASS PERIOD: March 2, 2023 to February 27, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) IAS was experiencing a new material trend of increased competitive pricing pressures and as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (ii) IAS’s pricing function was no longer “favorable” and IAS could not sustain its pricing and drive price increases; (iii) pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; (iv) the risks that competition “could result in increased pricing pressure” or “could put pressure on us to change our prices” had in fact transpired; and (v) as a result, the IAS’s public statements were materially false and misleading at all relevant times.

DEADLINE: March 31, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/integral-ad-science-loss-submission-form/?id=138490&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of IAS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 31, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903



The Gross Law Firm Notifies Elastic N.V. Investors of a Class Action Lawsuit and Upcoming Deadline – ESTC

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Elastic N.V. (NYSE: ESTC).

Shareholders who purchased shares of ESTC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/elastic-n-v-loss-submission-form/?id=138492&from=3

CLASS PERIOD: May 31, 2024 to August 29, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Elastic had implemented significant changes to its sales operations, particularly with respect to its customer segments in the Americas; (ii) the foregoing changes were likely to, and did, disrupt Elastic’s sales operations during the first quarter of its FY 2025; (iii) accordingly, defendants had overstated the stability of Elastic’s sales operations; (iv) as a result of all the foregoing, Elastic was unlikely to meet its own previously issued revenue guidance for its FY 2025; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

DEADLINE: April 14, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/elastic-n-v-loss-submission-form/?id=138492&from=3 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ESTC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 14, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected] 
Phone: (646) 453-8903